Jinsong Li

机构：Shanghai Jiao Tong University, Chinese Academy of Sciences, ShanghaiTech University, First Affiliated Hospital of Sichuan Medical University, China Animal Disease Control Center, Institute of Biophysics, Chinese Institute for Brain Research, Center for Excellence in Molecular Cell Science, Luye Pharma (China), Shanghai Clinical Research Center, Children's Hospital of Fudan University, University of Chinese Academy of Sciences · ORCID：0000-0003-3456-662X

发表论文 484 篇 · 总被引 16034 次 · h-index 59

代表论文

• Mitochondria-targeted MXene@MnO2-TPP nanoheterostructures for synergistic enhancement of sonodynamic therapy and immunotherapy in osteosarcoma (2025 · Bioactive Materials · 被引 12)
• Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system (2025 · Frontiers in Pharmacology · 被引 8)
• Development of a prognostic model for osteosarcoma based on macrophage polarization-related genes using machine learning: implications for personalized therapy (2025 · Clinical and Experimental Medicine · 被引 7)
• Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma (2025 · Discover Oncology · 被引 6)
• In vivo base editing of Chd3 rescues behavioural abnormalities in mice (2026 · Nature · 被引 5)
• Gastrula‐Premarked Posterior Enhancer Primes Posterior Tissue Development Through Cross‐Talk with TGF‐β Signaling Pathway (2025 · Advanced Science · 被引 3)